Overview

Epidemiologic Reviews

Volumn 21, Issue 1, 1999, Pages 1-6

  Rabinovich, N Regina ^a   Orenstein, Walter A ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DIS CONTR AND PREV   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE TRANSMISSION; HUMAN; INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; UNITED STATES; VACCINATION;

EID: 0032880121     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a017985     Document Type: Review

References (51)

1. Ten great public health achievements - United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999;48:241-3.
2. Impact of vaccines universally recommended for children -United States, 1990-1998. MMWR Morb Mortal Wkly Rep 1999;48:243-8.
3. Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication. Geneva, Switzerland: World Health Organization, 1988.
4. Certification of poliomyelitis eradication - the Americas, 1994. MMWR Morb Mortal Wkly Rep 1994;43:720-2.
5. de Quadros CA, Olivé JM, Hersh BS, et al. Measles elimination in the Americas: evolving strategies. JAMA 1996;275: 224-9.
6. Progress toward global measles control and regional elimination, 1990-1997. MMWR Morb Mortal Wkly Rep 1998; 47:1049-54.
7. Recommended childhood immunization schedule - United States, 1999. MMWR Morb Mortal Wkly Rep 1999;48: 12-16.
8. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349:1191-7.
9. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998;338:1405-12.
10. Clements DA, Langdon L, Bland C, et al. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995;149:1113-17.
11. King GE, Markowitz LE, Patriarca PA, et al. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J 1991;10:883-8.
12. Markowitz LE, Preblud SR, Orenstein WA, et al. Patterns of transmission in measles outbreaks in the United States, 1985-1986. N Engl J Med 1989;320:75-81.
13. Gustafson TL, Lievens AW, Brunell PA, et al. Measles out-break in a fully immunized secondary-school population. N Engl J Med 1987;316:771-4.
14. Recommendations of the Immunization Practices Advisory Committee (ACIP). Measles prevention. MMWR Morb Mortal Wkly Rep 1989;38(suppl 9):1-18.
15. Witte JJ, Karchmer AW, Case G, et al. Epidemiology of rubella. Am J Dis Child 1969;118:107-11.
16. Recommendation of the Public Health Service Advisory Committee on Immunization Practices. Am J Dis Child 1969;118:397-9.
17. Orenstein WA, Hinman AR, Rodewald LE. Public health considerations - United States. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: Saunders, 1999:1006-32.
18. Prevention of Lyme disease through active immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep (in press).
19. Edwards KM, Decker MD, Mortimer EA Jr. Pertussis vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: Saunders, 1999:293-344.
20. Baptista Risi J Jr. The control of poliomyelitis in Brazil. Rev Infect Dis 1984;6(suppl 2):S400-3.
21. Hull HF, Ward NA, Hull BP, et al. Paralytic poliomyelitis-seasoned strategies, disappearing disease. Lancet 1994;343: 1331-7.
22. de Quadros CA, Andrus JK, Olivé JM, et al. Eradication of poliomyelitis: progress in the Americas. Pediatr Infect Dis J 1991;10:222-9.
23. Chen RT. Safety of vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: Saunders, 1999: 1144-63.
24. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-23.
25. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
26. Ray P, Black S, Shinefield H, et al. Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA 1997;278:551-6.
27. Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, and the American Academy of Family Physicians: use of reminder and recall by vaccination providers to increase vaccination rates. MMWR Morb Mortal Wkly Rep 1998;47:715-17.
28. National Vaccine Advisory Committee. United States vaccine research: a delicate fabric of public and private collaboration. Pediatrics 1997;100:1015-20.
29. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;45(RR-11):1-36.
30. Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;48(RR-2):1-20.
31. The CVI Strategic Plan. Managing opportunity and change: a vision of vaccination for the 21st century. Geneva, Switzerland: The Children's Vaccine Initiative, 1997:47-8.
32. Institute of Medicine, National Academy of Sciences. Vaccines for the 21st century: a tool for decision-making. Washington, DC: National Academy Press, 1999.
33. Institute of Medicine, National Academy of Sciences. Vaccines for the 21st century: a tool for decision-making. Executive summary. Washington, DC: National Academy Press, 1999. (http://www.nap.edu).
34. Hadler SC. Cost benefit of combining antigens. Biologicals 1994;22:415-18.
35. Lieu TA, Cochi SL, Black SB, et al. Cost effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-81.
36. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases. The Jordan Report: report on the accelerated development of vaccines. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1998.
37. Belshe R, Iacuzio D, Mendelman P, et al. Efficacy of a trivalent live attenuated intranasal influenza vaccine in children. (Abstract S-116). Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998.
38. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente Efficacy Trial. (Abstract LB-9). Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998.
39. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 1983;2:355-7.
40. Walsh EE, Falsey AR, Hennessey PA. Epidemiology and clinical impact of respiratory syncytial virus (RSV) infection in adults with cardiopulmonary disease. (Abstract H-108). Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998.
41. Crowe JE Jr, Collins PL, Chanock RM, et al. Vaccines against respiratory syncytial virus and parainfluenza virus type 3. In: Levine MM, Woodrow GC, Kaper JB, et al., eds. New generation vaccines. 2nd ed. New York, NY: Marcel Dekker, 1997:711-18.
42. Tindle RW, Frazer IH. Vaccine against papillomavirus infections. In: Levine MM, Woodrow GC, Kaper JB, et al., eds. New generation vaccines. 2nd ed. New York, NY: Marcel Dekker, 1997:767-81.
43. Fedson DS. Adult immunization: summary of the National Vaccine Advisory Committee report. JAMA 1994;272: 1133-7.
44. Influenza and pneumococcal vaccination levels among adults aged ≥65 years - United States, 1997. MMWR Morb Mortal Wkly Rep 1998;47:797-802.
45. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR Morb Mortal Wkly Rep 1996;45(RR-13):1-16.
46. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
47. Sisk JE, Moskowitz AJ, Whang W, et al. Cost effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-9.
48. Poland GA. Adult immunization practice: the new paradigm. Am J Infect Control 1994;22:39-41.
49. Albright JW. The challenge of vaccinating the elderly. In: The Jordan Report: accelerated development of vaccines. Bethesda, MD: National Institute of Allergy and Infectious Diseases, 1996:37-42.
50. Parkman PD, Hopps HE, Albrecht P, et al. Simultaneous administration of vaccines. In: Halsey NA, de Quandros CA. Recent advances in immunization. Washington, DC: Pan American Health Organization, 1983:65-80. (PAHO scientific publication no. 451).
51. Decker MD, Edwards KM. Combination vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: Saunders, 1999:508-30.